Healthcare -
Biotechnology - NASDAQ - US
$ 1.065
-10.1 %
$ 65.6 M
Market Cap
-0.81
P/E
1. INTRINSIC VALUE
Balance Sheet
Pyxis Oncology, Inc.
| Current Assets | 132 M |
| Cash & Short-Term Investments | 127 M |
| Receivables | 0 |
| Other Current Assets | 5.51 M |
| Non-Current Assets | 24.7 M |
| Long-Term Investments | 0 |
| PP&E | 22.1 M |
| Other Non-Current Assets | 2.6 M |
| Current Liabilities | 17.7 M |
| Accounts Payable | 4.86 M |
| Short-Term Debt | 0 |
| Other Current Liabilities | 12.8 M |
| Non-Current Liabilities | 18.8 M |
| Long-Term Debt | 0 |
| Other Non-Current Liabilities | 18.8 M |
EFFICIENCY
Earnings Waterfall
Pyxis Oncology, Inc.
| Revenue | 16.1 M |
| Cost Of Revenue | 475 K |
| Gross Profit | 15.7 M |
| Operating Expenses | 105 M |
| Operating Income | -89.5 M |
| Other Expenses | -12.1 M |
| Net Income | -77.3 M |
RATIOS
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Pyxis Oncology, Inc.
| Net Income | -77.3 M |
| Depreciation & Amortization | 2.98 M |
| Capital Expenditures | -237 K |
| Stock-Based Compensation | 12.9 M |
| Change in Working Capital | 0 |
| Others | -9.29 M |
| Free Cash Flow | -57.9 M |
Wall Street Analysts Price Targets
Pyxis Oncology, Inc.
Wall Street analysts predict an average 1-year price target for PYXS of $8.8 , with forecasts ranging from
a
low of
$7 to a high of $10 .
PYXS Lowest Price Target
Wall Street Target
7 USD
557.28%
PYXS Average Price Target
Wall Street Target
8.8 USD
726.29%
PYXS Highest Price Target
Wall Street Target
10 USD
838.97%
4. DIVIDEND
ANALYSIS
PYXS does not distribute dividends.
5. COMPETITION
6. Ownership
Insider Ownership
Pyxis Oncology, Inc.
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
174 K USD 1
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Gene signatures associated with increased efficacy of micvotabart pelidotin (MICVO) due to greater linker cleavage were identified based on differential gene expression analysis of PDX responders/non-responders
globenewswire.com
- 3 weeks ago
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
Innovation is at its peak for the Zacks Medical-Drugs industry. AUPH, HRTX, ESPR, PYXS and PSTV may prove to be good additions to one's portfolio.
zacks.com
- 3 weeks ago
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
If the cancer space appeals to you, it's time to consider stocks like Pyxis Oncology, Verastem Oncology and Relay Therapeutics.
zacks.com
- 1 month ago
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D., President, Chief Executive Officer and Chief Medical Officer, will participate in a fireside chat at the Stifel 2025 Virtual Targeted Oncology Forum on Wednesday, April 9, 2025, at 11:30 a.m. ET. The Company will also be holding one-on-one investor meetings at the event.
globenewswire.com
- 1 month ago
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Expression data from patient-derived xenograft (PDX) mouse models exposed to micvotabart pelidotin (MICVO) indicate gene signatures associated with efficacy, deepening understanding of MOA and potential patient response
globenewswire.com
- 1 month ago
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
- Recently reported positive preliminary data from Phase 1 dose escalation trial of micvotabart pelidotin (“MICVO,” formerly PYX-201), including a confirmed 50% objective response rate by RECIST 1.1 in recurrent and metastatic head and neck squamous cell carcinoma (R/M HNSCC) - Received Fast Track Designation from the U.S. Food and Drug Administration for MICVO for the treatment of adult patients with R/M HNSCC whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 therapy - Initiated monotherapy expansion cohorts of MICVO for 2L and 3L R/M HNSCC patients who have received prior platinum-based chemotherapy and prior PD-(L)1 inhibitor therapy with preliminary data expected in 2H25 and 2/3L R/M HNSCC patients who have received prior EGFRi and PD-1 inhibitor therapy with preliminary data expected 1H26 - Initiated MICVO in combination with Merck's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), in 1/2L+ R/M HNSCC patients as part of a recently announced Clinical Trial Collaboration Agreement with Merck (known as MSD outside of the US and Canada) with preliminary data expected in 2H25 - Streamlined organization and implemented operational initiatives to focus resources on the execution of the MICVO clinical program, including workforce reduction of approximately 20% - Expected cash runway into 2H26 BOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today reported financial results for the year and quarter ended December 31, 2024, and provided a business update. “We are committed to the development of a novel therapy for patients with recurrent or metastatic head and neck squamous cell carcinoma who will progress following platinum-based therapies and prior PD-(L)1 therapy, and those that progress after current and emerging EGFRi therapies,” said Lara S.
globenewswire.com
- 2 months ago
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
BOSTON, March 03, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced that Lara S. Sullivan, M.D.
globenewswire.com
- 2 months ago
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer
Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody
globenewswire.com
- 2 months ago
Pyxis Oncology Initiates New PYX-201 Combination Trial and Initiates Cohort Expansions of Ongoing Monotherapy Trial
- Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck's KEYTRUDA® (pembrolizumab) in multiple solid tumors
globenewswire.com
- 3 months ago
Pyxis Oncology Announces Portfolio Prioritization, Focusing Resources on its Lead Clinical Program, PYX-201
- The Company will focus resources on advancing its lead asset, PYX-201 - PYX-201 is a novel first-in-concept antibody-drug conjugate (ADC) where significant RECIST responses were seen in head and neck squamous cell carcinoma (HNSCC) with additional potential in other solid tumors - Current cash runway expected to fund development into 2H 2026 BOSTON, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. In November 2024, Pyxis Oncology reported positive preliminary data from the ongoing Phase 1 dose-escalation study of PYX-201, evaluating its safety and efficacy in multiple solid tumor types.
globenewswire.com
- 4 months ago
Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead
Pyxis Oncology's lead candidate, PYX-201, showed promising response rates in Phase 1 trials but raised safety concerns due to a patient's death. The company's valuation appears deeply discounted, with a P/B ratio of 0.7 compared to a sector median of 2.4, reflecting market pessimism. PYX-201's ongoing trials and upcoming catalysts in 2025-2026 are crucial for addressing safety concerns and demonstrating efficacy across multiple cancer types.
seekingalpha.com
- 5 months ago
Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
On Wednesday, Pyxis Oncology, Inc. PYXS released preliminary data from the ongoing Phase 1 clinical dose escalation study evaluating PYX-201 in multiple solid tumors.
benzinga.com
- 5 months ago
8. Profile
Summary
Pyxis Oncology, Inc. PYXS
COUNTRY
US
INDUSTRY
Biotechnology
MARKET CAP
$ 65.6 M
Dividend Yield
0.00%
Description
Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targeting antibody for the treatment of thyroid cancer, head and neck squamous cell carcinoma, non-small cell lung cancer (NSCLC), and other solid tumors; and PYX-102, an investigational immune-therapeutic for treatment of solid tumors. The company's antibody drug conjugate (ADC) product candidates comprise of PYX-201, an investigational novel ADC to treat NSCLC, breast cancer, and other solid tumors; PYX-202, an investigational novel ADC for treatment of SCLC, soft tissue sarcoma, and other solid tumors; and PYX-203, an investigational ADC for the treatment of acute myeloid leukemia and myeloid dysplastic syndrome. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Contact
35 Cambridgepark Drive, Cambridge, MA, 02140
https://www.pyxisoncology.com
IPO
Date
Oct. 8, 2021
Employees
44
Officers
Dr. Michael Bui
Head of Global Regulatory Affairs
Dr. Supriya Roth Ph.D.
Head of Commercial Development
Dr. Shui He Ph.D.
Head of Biometrics
Dr. Lara S. Sullivan M.D., MBA
Chief Executive Officer, President, Chief Medical Officer & Director
Ms. Pamela Yanchik Connealy M.B.A.
Chief Financial Officer & Chief Operating Officer
Mr. Stephen T. Worsley MBA
Senior Vice President & Chief Business Officer
Dr. Hongwei Wang M.D., Ph.D.
Head of ADC Development & Clinical Strategy
Dr. Balu N. Balasubramanian Ph.D.
Interim Chief Technology Officer
Dr. Jan Pinkas Ph.D.
Chief Scientific Officer
Dr. Charles T. Gombar Ph.D.
Senior Vice President of Portfolio & Program Management